Countdown for AIDS treatment overcoming ‘Stribild’ to launch in Korea
A Gilead Sciences’ new 4-substance complex drug ‘Genvoya’ acquired approval to commercialize in Korea. Thus, Gilead is expected to consolidate its position in the HIV treatment market.
According to the industry concerned on the 20th, the Ministry of Food and Drug Safety recently approved commer...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
